EANM Marie-Curie Award 2021 went to VIVIANE TSCHAN

Viviane Tschan, PhD student in the “Nuclide Chemistry” group at the Center for Radiopharmaceutical Sciences, received this year’s Marie Curie Award for a new concept of radioligand therapy of prostate cancer, presented at the 34st Annual Conference of the European Association of Nuclear Medicine (EANM).

The preclinical research study demonstrated the favorable effect of a new PSMA radioligand (177Lu-Ibu-DAB-PSMA) compared to that of the clinically-applied 177Lu-PSMA-617 for the treatment of prostate cancer. Ibu-DAB-PSMA was previously established in the “Nuclide Chemistry” group by Deberle & Benesova et al. (Theranostics 2020). It is characterized by a chemical modification with ibuprofen as an albumin-binding entity to enhance the blood circulation time and, as a result, increase the tumor uptake.